SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 11/14/19 Escalon Medical Corp 10-Q 9/30/19 51:3.8M |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 316K 2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 17K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 18K 20: R1 Document And Entity Information HTML 42K 42: R2 Consolidated Balance Sheets HTML 116K 48: R3 Consolidated Balance Sheets (Parenthetical) HTML 32K 30: R4 Consolidated Statements Of Operations HTML 78K 19: R5 Consolidated Statements Of Shareholders' Equity HTML 39K and Comprehensive Loss 40: R6 Consolidated Statements Of Cash Flows HTML 100K 47: R7 Organization and Description of Business HTML 22K 31: R8 Going concern (Notes) HTML 22K 18: R9 Significant Accounting Policies HTML 106K 26: R10 Discontinued operation (Notes) HTML 56K 14: R11 Related Party Transactions HTML 27K 38: R12 Line of credit (Notes) HTML 23K 46: R13 Concentration of credit risk (Notes) HTML 36K 25: R14 Retirement and post retirement plans (Notes) HTML 22K 13: R15 Significant Accounting Policies (Policies) HTML 201K 37: R16 Leases (Policies) HTML 82K 45: R17 Significant Accounting Policies (Tables) HTML 82K 27: R18 Concentration of credit risk (Tables) HTML 39K 12: R19 Retirement and post retirement plans (Tables) HTML 19K 34: R20 Inventories (Tables) HTML 39K 50: R21 Leases (Tables) HTML 122K 24: R22 Going concern (Details) HTML 19K 22: R23 Significant Accounting Policies (Cash and Cash HTML 21K Equivalents) (Details) 33: R24 Significant Accounting Policies (Inventory) HTML 28K (Details) 49: R25 Significant Accounting Policies (Accounts HTML 18K Receivable) (Details) 23: R26 Significant Accounting Policies (Net Income (loss) HTML 30K Per Share) (Details) 21: R27 Significant Accounting Policies Earning per share HTML 61K details (Details) 32: R28 Significant Accounting Policies Goodwill and HTML 18K intangible assets (Details) 51: R29 Significant Accounting Policies deferred revenue HTML 22K (Details) 43: R30 Discontinued operation (Details) HTML 37K 35: R31 Related Party Transactions (Details) HTML 45K 15: R32 Line of credit (Details) HTML 53K 28: R33 Concentration of credit risk (Details) HTML 74K 44: R34 Revenue from contracts with customers (Details) HTML 22K 36: R35 Retirement and post retirement plans (Details) HTML 31K 16: R36 Leases (Details) HTML 62K 17: R9999 Uncategorized Items - esmc-20190930.xml HTML 20K 41: XML IDEA XML File -- Filing Summary XML 85K 29: EXCEL IDEA Workbook of Financial Reports XLSX 51K 6: EX-101.INS XBRL Instance -- esmc-20190930 XML 872K 8: EX-101.CAL XBRL Calculations -- esmc-20190930_cal XML 122K 9: EX-101.DEF XBRL Definitions -- esmc-20190930_def XML 398K 10: EX-101.LAB XBRL Labels -- esmc-20190930_lab XML 948K 11: EX-101.PRE XBRL Presentations -- esmc-20190930_pre XML 578K 7: EX-101.SCH XBRL Schema -- esmc-20190930 XSD 87K 39: ZIP XBRL Zipped Folder -- 0000862668-19-000017-xbrl Zip 129K
Exhibit |
1. | I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Chief Executive Officer | |
Date: November 14, 2019 |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/14/19 | None on these Dates | ||
For Period end: | 9/30/19 | |||
List all Filings |